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Abstract: Naftopidil, approved only in Japan, is an α1-adrenergic receptor antagonist 
(α1-blocker) used to treat lower urinary tract symptoms (LUTS) suggestive of benign prostatic 
hyperplasia (BPH). Different from tamsulosin hydrochloride and silodosin, in that it has higher 
and extremely higher affinity respectively, for the α1A-adrenergic receptor subtype than for 
the α1D type, naftopidil has distinct characteristics because it has a three times greater affinity 
for the α1D-adrenergic receptor subtype than for the α1A subtype. Although well-designed 
large-scale randomized controlled studies are lacking and the optimal dosage of naftopidil is 
not always completely determined, previous reports from Japan have shown that naftopidil has 
superior efficacy to a placebo and comparable efficacy to other α1-blockers such as tamsulosin. 
On the other hand, the incidences of ejaculatory disorders and intraoperative floppy iris syndrome 
induced by naftopidil may be lower than for tamsulosin and silodosin having high affinity for 
the α1A-adrenergic receptor subtype. However, it remains unknown if the efficacy and safety 
of naftopidil in Japanese is applicable to white, black and Hispanic men having LUTS/BPH in 
western countries.
Keywords: benign prostatic hyperplasia, lower urinary tract symptoms, α1-blocker, 
naftopidil
Introduction
Benign prostatic hyperplasia (BPH) is a histological condition that is commonly 
observed in elderly men.1 BPH is an adenoma composed of a mixture of increased 
numbers of epithelial and/or stromal cells. Benign enlargement of the prostate (BPE) 
due to BPH induces bladder outlet obstruction (BOO) and results in the development 
of lower urinary tract symptoms (LUTS). There are two mechanisms involved in the 
development of BOO: mechanical obstruction due to increased volume of the prostate; 
and functional obstruction due to increased tone of the prostatic smooth muscle. In 
addition, BOO secondarily affects bladder function. Either detrusor overactivity during 
the filling phase or detrusor underactivity during the voiding phase, or a combination 
of both conditions, modifies LUTS in elderly men with BOO.
There are two mainstays of medical treatment for LUTS suggestive of BPH (LUTS/
BPH): 5α-reductase inhibitors (5ARI); and α1-adrenergic receptor (AR) antagonists 
(α1-blockers).2 5ARI (finasteride, dutasteride) improve BOO through reduction of 
the prostate volume and contribute to gradual improvement of LUTS and long-term 
inhibition of disease progression. On the other hand, α1-blockers improve BOO 
through a decrease of tone of the prostatic smooth muscle. Several α1-blockers are 
clinically available, including those having nonspecific affinity for α1-AR subtypes Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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(prazosin, terazosin, doxazosin, alfuzosin) and those having 
specific affinity for them (tamsulosin, naftopidil, silodosin). 
Although several large-scale studies3–5 have demonstrated 
recently that combination of a 5 ARI and α1-blocker is supe-
rior to either 5 ARI or α1-blocker monotherapy in terms of 
improvement of subjective and objective urinary symptoms 
as well as the long-term inhibition of BPH-related events 
such as acute urinary retention and conversion to surgical 
treatment, α1-blockers are still essential as first-line medical 
treatments for patients having LUTS/BPH with problems, 
because symptomatic improvement can be achieved rapidly 
with α1-blockers.
Naftopidil, with three times greater affinity for α1D 
than for the α1A-AR subtype, is an α1-blocker that has 
been approved for clinical use for LUTS/BPH only in Japan 
since 1999.6 Two Japanese clinical guidelines, the Clinical 
Guideline for Male Lower Urinary Tract Symptoms7 and 
Clinical Guideline for Benign Prostatic Hyperplasia,8 recom-
mend the use of naftopidil for male LUTS/BPH as a grade A 
recommendation. At present, naftopidil has the second high-
est use, following tamsulosin, in Japan. However, due to the 
limited number of English reports on naftopidil and doctors 
being unable to use it in other countries, the clinical charac-
teristics of this drug have not been sufficiently introduced. 
Although the English literature on naftopidil up to January 
2009 was comprehensively summarized in a review article 
written by Garimella et al,9 several important studies writ-
ten in Japanese were missed because only reports published 
in English were reviewed. In this article, the efficacy and 
safety of naftopidil for LUTS/BPH are reviewed based on 
the English literature published up to March 2011 as well as 
several important Japanese reports such as the results of a 
randomized placebo-controlled trial conducted in Japan.
Pharmacological characteristics  
of naftopidil
Naftopidil ((±)-1-[4-(2-methoxyphenyl)piperazinyl]-3-
(1-naphthyloxy) propan-2-ol, Figure 1) is an α1-blocker 
produced by Boehringer Mannheim, Germany. In vitro 
study has shown that naftopidil binds to α1-AR in human 
BPH tissue.10 It has a threefold higher affinity for α1D than 
for the α1A-AR subtype, whereas tamsulosin and silodosin 
have threefold and 56-fold higher affinities for the α1A-AR 
subtype than for the α1D subtype, respectively (Table 1).6,11 
In an in vivo study using anesthetized male mongrel dogs, 
not only prostatic pressure but also blood pressure increased 
by phenylephrine was significantly decreased by intravenous 
administration of naftopidil in a dose-dependent manner. The 
inhibition of prostatic pressure was more remarkable than that 
of blood pressure.6 Thus, as it appeared to be a promising 
α1-blocker with selectivity for the prostate, a phase I clini-
cal study of naftopidil was conducted.12 Naftopidil, 12.5 to 
100 mg, was given to 15 healthy adult Japanese male vol-
unteers. With a single administration of 50 mg of naftopidil 
after food, the means ± standard deviations of Tmax (hour), Cmax 
(ng/mL), T1/2b (hour), AUC0-∞ (ng · hour/mL) and Clt (L/hour) 
were 2.20 ± 1.04, 58.6 ± 24.2, 13.2 ± 5.4, 311.6 ± 54.3 and 
164.2 ± 26.9, respectively. The recovery of the intact form of 
naftopidil in urine was not more than 0.01%. Although there 
were no abnormal findings in clinical laboratory tests, 4 of 
the 5 subjects who received a single administration of 100 mg 
of naftopidil reported headaches, cold sweats, facial pallor, 
sleepiness and postural hypotension. Naftopidil is excreted 
into bile after being primarily metabolized by CYP2C9 and 
CYP3A4 in the liver microsomes.13
Rationale for naftopidil treatment 
of LUTS suggestive of BPH
Different from tamsulosin and silodosin, which have higher 
and extremely higher affinity for the α1A-AR subtype than 
for the α1D-AR subtype, respectively, naftopidil has distinct 
characteristics because it has threefold affinity for the α1D 
subtype than for the α1A-AR subtype.6,11 Since the tissue 
of BPH shows nine- and threefold increased expression of 
mRNA of α1A and α1D-AR subtypes, respectively, com-
pared to normal prostatic tissue,14 it has been speculated that 
not only α1A but also α1D-AR contributes to contraction of 
O
OH
NN CH2CHCH2
OCH3
Figure 1 Chemical structure of naftopidil (C24H28N2O3), molecular weight 392.5.
Table 1 Affinities of naftopidil, tamsulosin and silodosin to cloned 
human α1-adrenergic receptors6,11
Ki (nM)
α1a α1b α1d
Takei et al6
  Naftopidil 3.7 ± 0.6 20 ± 1 1.2 ± 0.0
  Tamsulosin 0.019 ± 0.002 0.29 ± 0.02 0.063 ± 0.011
Shibata et al11
  Silodosin 0.036 ± 0.010 21 ± 5 2.0 ± 0.4Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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prostatic smooth muscle. Recently, an interesting observation 
was reported by Kojima et al.15 The expression of mRNA of 
the α1-AR subtype in the prostate biopsy specimens of 61 
patients having LUTS/BPH was investigated using quanti-
tative reverse transcriptase-polymerase chain reaction. Of 
the 61 prostates, 34 (55.7%) and 27 (44.3%) had dominant 
expression of α1a and α1d, respectively. As discussed in 
detail later, tamsulosin and naftopidil were more effective in 
patients with dominant expression of α1a and α1d, respec-
tively. Thus, in approximately half of the patients having 
LUTS/BPH, the efficacy of the α1D/α1A blocker naftopidil 
may be more promising than that of the α1A/α1D blocker 
tamsulosin.
The α1D-AR subtype may be involved in detrusor over-
activity associated with BOO causing overactive bladder 
syndrome (OAB), since increased expression of mRNA of 
the α1D-AR subtype in human detrusor muscle and human 
lumbosacral spinal cord has been demonstrated.16,17 Several 
animal studies using rats and mice have demonstrated that 
the micturition reflex is facilitated by the α1D-AR subtype 
on urothelial cells.18,19 In addition, it has been demonstrated 
that naftopidil has an inhibitory effect on C-fiber afferents 
because the drug increases bladder capacity in rats with 
cerebral infarction, but not in C-fiber desensitized rats with 
cerebral infarction.20 Thus, naftopidil, with a higher affin-
ity for the α1D-AR subtype, may contribute to improving 
detrusor overactivity through the blockade of the α1D-AR 
subtype not only in the prostate but also in nonprostatic 
organs.
Dose-finding study and randomized 
placebo-controlled study conducted 
in Japan
After the phase I clinical study,12 a late phase II clinical study 
was conducted to determine the efficacy, safety and optimal 
dosage of naftopidil.21 In the study, naftopidil was given to 
133 patients with LUTS/BPH. After a 1-week run-in period 
using a placebo, 25 mg/day naftopidil was given for 2 weeks, 
then the dosage was escalated to 50 mg/day and given for 
the next 2 weeks. If the efficacy of 50 mg/day naftopidil was 
insufficient based on the assessment of investigators, the dos-
age was escalated to 75 mg/day and given for an additional 
2 weeks (n = 47). Dose-dependent improvements of LUTS 
and the maximum flow rate (Qmax) were observed. Although 
3 patients (2.3%) reported adverse events, no serious adverse 
events were observed. The buzzing or lightheadedness in 2 
patients with 25 mg/day naftopidil, and hypotension in 1 
patient with 50 mg/day naftopidil spontaneously disappeared 
after termination or dose reduction of naftopidil. Thus, the 
optimal dosage is thought to be 25 mg to 75 mg/day.
Yasuda et al evaluated the urodynamic effect of naftopidil 
using a pressure-flow study.22 Naftopidil, 25 to 75 mg/day, 
was given to 32 patients aged 52 to 78 years (mean 66.3 
years) with LUTS/BPH for 4 to 6 weeks. Before and after 
treatment, uroflowmetry, determination of post-void residual 
urine (PVR), urethral pressure profile, filling cystometry 
and pressure-flow study were performed. The mean Qmax 
(n = 28) and PVR (n = 28) significantly increased from 9.9 
to 14.3 mL/second (P , 0.001) and decreased from 48.1 to 
19.3 mL (P , 0.05), respectively. The mean urethral pressure 
profile (n = 14) and cystometry (n = 23) showed a significant 
decrease of maximum urethral closure pressure from 69.0 to 
58.8 cm H2O (P , 0.05) and an increase of the first desire 
to void from 193.5 to 238.7 mL (P , 0.05), respectively. 
Although the mean opening pressure and pressure at the 
maximum flow rate in the pressure-flow study (n = 14) did 
not change significantly, from 59.9 to 71.9 cm H2O and 73.5 
to 71.5 cm H2O, respectively, the mean minimum urethral 
resistance significantly decreased from 1.7 to 0.9 (P , 0.05). 
Thus, it is likely that naftopidil urodynamically improves 
BOO induced by BPH.
A double-blind randomized placebo-controlled trial was 
conducted between 1993 and 1995 in Japan.23 Although 
the results were reported in Japanese in 1997, it remains 
the only randomized placebo-controlled trial. Based on the 
results of a double-blind study comparison with prazosin 
hydrochloride,24 naftopidil was approved by the Japanese 
Regulatory Authority for treatment for LUTS/BPH in 1999. 
In the double-blind randomized placebo-controlled trial,23 
333 patients having LUTS/BPH were randomly allocated 
into 4 groups after at least a 1-week run-in period using 
a placebo, a placebo for 4 weeks (placebo group, n = 79), 
25 mg/day naftopidil for 4 weeks (25 mg group, n = 86), 
25 mg/day naftopidil for 1 week followed by 50 mg/day 
naftopidil for 3 weeks (50 mg group, n = 86), and 25 mg/day 
naftopidil for 1 week followed by 75 mg/day naftopidil for 
3 weeks (75 mg, n = 82). Although changes in LUTS were 
not evaluated by the International Prostatic Symptom Score 
(IPSS) because it was not validated in Japanese at that time, 
improvements of the subjective urinary symptoms and 
Qmax in the 50 mg and the 75 mg groups were significantly 
superior to the placebo group. There was no significant 
difference in the development of adverse events among the 
groups. Thus, 50 mg and 75 mg of naftopidil were recom-
mended as the standard dosages for treatment of LUTS/
BPH in Japan.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Randomized comparative studies  
of naftopidil compared with other  
α1-blockers and phytotherapy
There are 8 randomized studies of naftopidil compared 
with other α1-blockers (tamsulosin in 6, tansulosin and 
silodosin in 1) and phytotherapy (1) in the contemporary 
English literature using the IPSS for evaluation of LUTS 
after 2003 (Table 2).25–32 They consist of various inclusion 
criteria, study designs, treatment durations and analytical 
methods. A crossover design was applied to 3 studies.25,28,29 
Most of the studies recruited small numbers of patients 
without provision of the required sample size for the 
hypothesis test.
Ikemoto et al reported the efficacy of tamsulosin and 
naftopidil for 96 patients having LUTS/BPH with IPSS $ 8 
and Qmax , 12 mL/second.25 The 96 patients were randomly 
allocated into 2 groups. The naftopidil-to-tamsulosin group 
(N-T group, n = 43) received 50 mg/day naftopidil for 8 weeks 
(25 mg/day for the first 2 weeks) immediately followed by 
0.2 mg/day tamsulosin, which is the approved optimal dosage 
for treatment of LUTS suggestive of BPH in Japan, for 8 
weeks. The tamsulosin-to-naftopidil group (T-N group, n = 53) 
received 0.2 mg/day tamsulosin for 8 weeks and then 50 mg/day 
naftopidil for 8 weeks (25 mg/day for the first 2 weeks) without 
a washout period between the 2 drugs. Twelve (28%) and 18 
patients (34%) in the N-T and the T-N groups were withdrawn 
for several reasons including non-attendance at hospital 
appointments and adverse events. There was no significant dif-
ference in the incidence of adverse events between the 2 groups 
(3% versus 2%). The mean IPSS significantly decreased from 
17.0 at baseline to 8.5 at 16 weeks and 17.5 at baseline to 9.2 at 
16 weeks in the N-T and the T-N groups, respectively. Storage 
symptoms such as daytime frequency, urgency, and nocturia 
were significantly improved only by naftopidil monotherapy, 
whereas voiding symptoms such as intermittency and straining 
were improved only by tamsulosin monotherapy. The QOL 
index and Qmax showed similar improvements in both groups. 
In 28 patients who reported “not effective” or “worse” for the 
initial treatment, the IPSS was improved by crossover to the 
other drug in 10 of the 12 patients in the N-T group and 16 
of the 16 patients in the T-N group. Thus, their study demon-
strated that a second α1-blocker may be effective even if the 
first α1-blocker is ineffective.
Yamanishi et al compared the clinical and urodynamic 
effects of naftopidil to those of phytotherapy with eviprostat.26 
Forty-nine patients (mean age 67.9 years) having LUTS/
BPH with IPSS $ 8, Qmax #12 mL/second, prostate volume 
(PV) $ 15 mL, and an obstructive or equivocal condition 
in a pressure-flow study were included in the study. After a 
1-week run-in period, the patients were randomly allocated 
into naftopidil (n = 36) and eviprostat (n = 13) groups at 
the ratio 3:1. In the naftopidil group, naftopidil was given 
at a dose of 25 mg/day for 2 weeks, followed by 50 mg/day 
for 2 weeks, and then 75 mg/day for another 2 weeks if the 
patients were not satisfied with the improvement of LUTS. In 
the other group with eviprostat, which is a mixture of plant 
extracts from Phila umbellata, Populus tremula and Pulsatilla 
pratensis, and wheat-germ oil, 6 tablets/day were given for 
6 weeks. Symptomatic improvements evaluated by the IPSS 
and QOL index were significantly better in the naftopidil 
group than in the eviprostat group. Although improvement 
of Qmax tended to be better in the naftopidil group, there was 
no significant difference (P = 0.0886). In the pressure-flow 
study, there was no improvement of detrusor pressure at 
the maximum flow rate by the treatments (naftopidil group, 
−8.9 cm H2O, P = 0.0865; eviprostat group, −10.2 cm H2O, 
P = 0.2015). There was no significant difference in the change 
of detrusor pressure at the maximum flow rate between the 
groups (P = 0.8879). On the other hand, the Abrams-Griffiths 
number was significantly decreased by naftopidil treatment 
(−14.6, P = 0.0422) but not by eviprostat treatment (−10.8, 
P = 0.1441), although no significant intergroup difference 
was observed (P = 0.7262). In the 19 patients having detrusor 
overactivity at baseline, it disappeared in 3 of the 14 patients 
(21%) in the naftopidil group but in none of the 5 patients 
in the eviprostat group. Thus, naftopidil was more effective 
than eviprostat in terms of symptomatic improvement of 
LUTS/BPH.
Gotoh et al compared the efficacy and safety of 
naftopidil and tamsulosin in a multicenter randomized 
trial.27 Men aged $50 years having LUTS/BPH with IPSS 
$ 8, Qmax , 15 mL/second, a voided volume of $150 mL, 
and PV $ 20 mL, were enrolled in the study. Of the 185 
enrolled patients, 144 were eligible for efficacy analysis 
and randomly allocated into groups receiving 0.2 mg/day 
tamsulosin for 12 weeks or 25 mg/day naftopidil for 2 weeks 
followed by 50 mg/day for 10 weeks. The IPSS and QOL 
index significantly improved in both groups (IPSS, −8.4 
in the tamsulosin group, P , 0.001, −5.9 in the naftopidil 
group, P , 0.001; QOL index, −1.4 in the tamsulosin group, 
P , 0.001, −1.3 in the naftopidil group, P , 0.001). There 
was no significant difference in the change of the IPSS 
between the groups at 12 weeks (P = 0.060), although the 
change of the IPSS in the tamsulosin group tended to be larger 
than with naftopidil. No intergroup differences were observed 
in any IPSS index after treatment. Qmax was significantly Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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improved by 2.1 mL/second in both groups (P , 0.001 and 
P = 0.001) and no intergroup difference after treatment was 
observed (P = 0.709). The adverse events were comparable, 
with no significant differences in systolic and diastolic blood 
pressure after treatment between the groups. Thus, the authors 
concluded that 50 mg of naftopidil was as effective and safe 
as 0.2 mg of tamsulosin.
Nishino et al investigated the efficacies of naftopidil 
and tamsulosin in a crossover design.28 Thirty-four patients 
(mean age 72.4 years) having LUTS/BPH with IPSS $ 8 
and Qmax , 15 mL/second were enrolled in the study. 
Seventeen patients were initially prescribed 50 mg/day 
naftopidil for 4 weeks, followed by 0.2 mg/day tamsulosin 
for 4 weeks after a 1-week washout period. For another 17 
patients, tamsulosin was initially prescribed followed by 1 
week of washout, and then naftopidil. Thus, all 34 patients 
received both naftopidil for 4 weeks and tamsulosin for 
4 weeks. There was no significant difference in the mean 
IPSS after treatment between naftopidil (8.9) and tamsu-
losin monotherapies (9.3, P = 0.265). Although there was 
no significant difference in the mean IPSS voiding symptom 
subscores after treatment between the groups (3.1 versus 
2.6, P = 0.134), the mean IPSS storage symptom subscore 
after treatment was higher with tamsulosin monotherapy 
(5.5) than with naftopidil monotherapy (4.8, P = 0.007). Of 
the storage symptoms after treatment, only nocturia showed 
a significant difference between the groups (2.3 versus 
3.1, P , 0.001). Although no significant difference in the 
mean Qmax after treatment was observed between naftopidil 
monotherapy (13.5 mL/second) and tamsulosin monotherapy 
(13.2 mL/second), the mean detrusor pressure at the 
maximum flow rate in the pressure-flow study after treatment 
was lower for tamsulosin monotherapy (61.2 cm H2O) than 
for naftopidil monotherapy (64.3 cm H2O, P = 0.002). On 
the other hand, the mean first desire to void and mean maxi-
mum desire to void were significantly higher with naftopidil 
monotherapy (188.4 mL, 339.4 mL) than with tamsulosin 
monotherapy (174.1 mL, P , 0.001; 334.9 mL, P = 0.036). 
Detrusor overactivity disappeared in 2 patients with naftopi-
dil but not in those with tamsulosin. The authors concluded 
that naftopidil was better than tamsulosin for improvement 
of storage symptoms, especially nocturia, as a result of the 
disappearance of detrusor overactivity and increase in the 
first desire to void.
Momose et al also reported the results of crossover 
between naftopidil and tamsulosin.29 Forty-five patients 
(mean age 66.9 years) having LUTS/BPH were included 
in the study. There were no symptomatic severity criteria 
for inclusion. The patients were randomly assigned to 
the N-T group (n = 20, 50 mg of naftopidil for 4 weeks 
followed by 0.2 mg/day tamsulosin for 4 weeks) and T-N 
group (n = 25, 0.2 mg/day tamsulosin for 4 weeks followed 
by 50 mg of naftopidil for 4 weeks). Although the IPSS 
was similarly improved during the first treatment period 
in both groups (19.6 to 12.9 in the N-T group, P , 0.01; 
18.4 to 11.1 in the T-N group, P , 0.01), after crossover 
the IPSS was slightly improved in the N-T group (12.9 to 
11.1) whereas it slightly deteriorated in the T-N group (11.1 
to 12.8). Tamsulosin was more effective than naftopidil for 
intermittency, nocturia, and the QOL index. The authors 
concluded that the therapeutic effects of 0.2 mg of tamsu-
losin on storage and voiding symptoms were superior to 
those of naftopidil.
Ukimura et al directly compared the efficacy of naftopidil 
and tamsulosin in patients having LUTS/BPH associated with 
nocturia.30 Patients aged $50 years having LUTS/BPH with 
nocturia $ 2, IPSS $ 8, QOL index $ 3, Qmax , 15 mL/
second, with a voided volume of $ 150 mL, PVR , 50 mL 
and PV , 50 mL were randomized into two groups, 50 mg/
day naftopidil for 6–8 weeks (n = 31) and 0.2 mg/day tam-
sulosin for 6–8 weeks (n = 28). The IPSS was significantly 
improved in both groups, from 17.2 to 7.8 (P = 0.0000) in 
the naftopidil group and from 18.9 to 9.2 (P = 0.0001) in the 
tamsulosin group without a significant intergroup difference 
at the end of the observation period (P = 0.98). The sum of day 
frequency and nocturia was improved earlier in the naftopidil 
group (7.0 at baseline, 4.4 at 2 weeks, 3.2 at 6–8 weeks) than 
in the tamsulosin group (6.8 at baseline, 4.9 at 2 weeks [versus 
naftopidil, P = 0.0489], 3.7 at 6–8 weeks [versus naftopidil, 
P = 0.10]). There were no significant differences in changes of 
Qmax and PVR between the 2 groups. The authors concluded 
that naftopidil provided early improvements of day frequency 
and nocturia compared with tamsulosin.
Masumori et al performed a head-to-head comparison of 
the efficacies of naftopidil and tamsulosin, although the study 
was conducted to investigate differences in the incidence of 
ejaculatory disorders as a primary endpoint. Ninety-five men 
aged $50 years (mean 64 years) having LUTS/BPH with 
IPSS $ 8 were enrolled in the study and randomly assigned 
to receive 50 mg/day of naftopidil (n = 48) or 0.2 mg/day of 
tamsulosin (n = 47) for 12 weeks.31 Although there were no 
significant differences in the changes in the Qmax and PVR 
caused by the treatments between the 2 groups, the changes 
in the IPSS were significantly higher in the tamsulosin group 
(from 17.8 to 10.6, −7.2) than in the naftopidil group (from 
15.0 to 11.2, −3.8, P = 0.013). Similarly, the improvement Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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in the QOL index in the tamsulosin group (from 4.7 to 2.8, 
−1.9) was larger than that in the naftopidil group (from 4.2 
to 3.2, −1.0, P = 0.013). Thus, the authors speculated that the 
efficacy of 0.2 mg of tamsulosin might be better than that of 
50 mg of naftopidil.
More recently, Yokoyama et al directly compared the 
effects of three different types of α1-blockers; naftopidil, 
tamsulosin, and silodosin, on LUTS, erectile dysfunction, 
and ejaculatory dysfunction.32 A total of 136 patients aged 
50–80 years having LUTS/BPH with IPSS $ 8 were enrolled 
in the study. They were randomly assigned to 3 groups, 
naftopidil at 50 mg once a day (n = 46), tamsulosin at 
0.2 mg once a day (n = 45), or silodosin at 4 mg twice a 
day (n = 45) for 12 weeks. The mean IPSS was significantly 
improved by treatment for 12 weeks in all 3 groups, from 
17.4 to 11.3 in the naftopidil group; 18.0 to 10.7 in the 
tamsulosin group, and from 18.7 to 13.8 in the silodosin 
group. No significant difference was observed in the IPSS 
at 12 weeks among the groups. Similarly, there were no sig-
nificant differences in the mean QOL index, Qmax, and PVR 
at 12 weeks among the groups. Thus, the authors concluded 
that the three α1-blockers similarly provided objective and 
subjective improvements in LUTS/BPH in the population 
they investigated.
Based on the results of the previous randomized studies 
comparing the efficacy of naftopidil to other α1-blockers, 
mainly tamsulosin, some reports demonstrated the compara-
tive efficacy,25,27,28,30,32 whereas others did not,29,31 although 
no study had sufficient statistical power to draw a solid 
conclusion. Kojima et al clearly showed that the dominant 
α1-AR subtype varied among individuals.15 They performed 
prostate biopsies for 61 patients having LUTS/BPH and the 
expression of mRNA in the α1-AR subtype in the speci-
mens was analyzed. Naftopidil, 50 mg/day and tamsulosin, 
0.2 mg/day were randomly given to 28 and 33 patients for 12 
weeks each. In the naftopidil group, α1a- and α1d-AR were 
dominant in the prostates of 12 and 16 patients, respectively. 
In the tamsulosin group, α1a- and α1d-AR were dominant 
in the prostates of 22 and 11 patients, respectively. There 
were no significant differences in the efficacies such as the 
IPSS, QOL index, Qmax, and PVR between the naftopidil 
and tamsulosin groups. However, in the naftopidil group, 
improvements of subjective and objective urinary symptoms 
were more remarkable in the patients with the α1d-AR domi-
nant subtype than in those in whom α1a-AR was dominant. 
Conversely, in the tamsulosin group, striking symptomatic 
improvements were observed in the patients with the α1a-AR 
dominant subtype. Thus, the response to α1-blockers may 
depend on the ratio of the expression level of the α1-AR 
subtype rather than on the type of α1-blocker.
Dose modification study
Even though 50 mg and 75 mg/day naftopidil were recom-
mended as standard dosages according to the phase III 
clinical study,23 no previous randomized studies allowed 
dose escalation up to 75 mg or a dosage of 75 mg as the 
starting dose. Yokoyama et al performed a randomized study 
to compare the efficacy and safety of 25 mg and 75 mg of 
naftopidil as the starting doses for patients aged 50–80 years 
having LUTS/BPH with IPSS $ 8, QOL index $ 2, nocturia 
$ 3, and PV $ 20 mL (Table 3).33 Naftopidil, 25 mg (n = 72) 
or 75 mg (n = 67) was randomly administered once a day for 
4 weeks. There were no differences in changes of the IPSS 
and QOL index between the groups. On the other hand, Qmax 
at the endpoint was significantly higher in the 75 mg group 
than in the 25 mg group (P , 0.05). In the patients having 
moderate symptomatic severity, the degree of improvement 
in voiding symptoms was greater in the 75 mg group than in 
the 25 mg group (P , 0.05). Since there was no significant 
difference in the incidence of adverse events between 25 mg 
(3.9%) and 75 mg (2.6%), they concluded that starting admin-
istration of 75 mg/day naftopidil should be considered for 
patients with moderate symptomatic severity. Kadekawa et al 
supported the clinical efficacy and safety of a naftopidil dose 
of 75 mg once a day for 4 weeks.34 Interestingly, Tsuritani 
et al demonstrated in a randomized trial that improvement of 
the mean IPSS after 8 weeks of treatment was significantly 
higher for 75 mg once daily in the evening (9.2) than with 
25 mg thrice daily (11.3, P = 0.0347) and that this was prob-
ably due to a difference in Cmax between them.35 A recent 
study demonstrated that dose escalation to 75 mg in patients 
with an insufficient response to 50 mg once a day for 12 
weeks (defined as improvement of the IPSS , 5) showed 
further improvement of subjective and objective urinary 
symptoms.36 On the other hand, Oh-oka reported the results 
of a dose-reduction study.37 For 100 patients having LUTS/
BPH, naftopidil was administrated once in the morning at 
a dose 75 mg for 6 weeks; then, following washout for 1 
week, a reduced dose of 50 mg was administered for another 
6 weeks. There was no significant difference in the mean 
IPSS after treatment between 75 mg (5.2) and 50 mg (5.3), 
although a significant improvement in urgency was found 
only after administration of 50 mg. In addition, there were no 
significant differences in objective measurements, including 
the parameters in a pressure-flow study, except for bladder 
compliance. Thus, 75 mg of naftopidil is not always superior Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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to 50 mg of naftopidil. It is highly likely that the optimal dos-
age of naftopidil varies among individuals based on different 
α1A/α1D-AR subtype ratios.
Effect of naftopidil on overactive 
bladder symptoms and nocturia
Several single-arm studies focused on the efficacy of 
naftopidil for OAB and nocturia associated with BPH.38–41 
Oh-oka showed that 75 mg of naftopidil was effective to 
decrease nocturnal frequency in 122 patients with remaining 
nocturia $ 3 even after treatment using 0.2 mg of tamsulosin 
for 6 weeks.38 Although detrusor overactivity was found in 40 
patients, it disappeared in 31 patients after 6 weeks of nafto-
pidil administration. Takahashi et al demonstrated the effi-
cacy of 50–75 mg/day naftopidil for 6 weeks for 81 patients 
(mean age 69 years) having LUTS/BPH with urgency/day 
$ 1, IPSS $ 8 and any of the scores for 3 items of the IPSS 
(day frequency, nocturia, urgency) $3.39 The mean scores 
for urgency on the IPSS, day frequency and nocturia on 
the 2-day frequency volume chart decreased from 3.1 to 
1.4 (P , 0.0001), 9.3 to 8.0 (P , 0.0001), and from 2.7 to 
2.0 (P , 0.0001), respectively. Significant improvement of 
nocturia was observed in both the patients with, and without, 
nocturnal polyuria. Interestingly, a tendency for nocturnal 
urine volume to decrease was observed in the patients with 
nocturnal polyuria (from 919 to 766 mL, P = 0.101). Thus, 
naftopidil was effective for nocturia in patients with LUTS 
regardless of the existence of nocturnal polyuria. Yokoyama 
et al reported that nocturia was well-controlled by naftopidil 
treatment, with decreased sleep disturbances.40 In addition, 
they demonstrated that nocturnal urine volume significantly 
decreased in the sleep disturbance group, perhaps through the 
central action of naftopidil on vasopressin secretion.
In general, α1-blocker monotherapy is effective to con-
trol not only voiding symptoms but also storage symptoms. 
However, α1-blocker monotherapy does not always control 
the storage symptoms. Recently, solid evidence to support 
the efficacy and safety of combination of α1-blockers and 
anticholinergic agents for male LUTS associated OAB has 
been reported.42–45 Maruyama et al compared the efficacy and 
safety of naftopidil monotherapy with combination therapy 
using naftopidil and anticholinergic agents for patients having 
LUTS/BPH with storage symptoms.46 Either monotherapy 
with 25–75 mg of naftopidil (n = 45) or combination therapy 
using 25–75 mg of naftopidil and an anticholinergic agent 
(10–20 mg of propiverine hydrochloride or 2–6 mg of oxy-
butynin hydrochloride, n = 41) was randomly given to 101 
patients with LUTS/BPH with IPSS $ 8, QOL index $ 3, 
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a score for day frequency $ 3, and a score for nocturia $ 2 for 
12 weeks. There were no significant differences in the IPSS, 
QOL index, and Qmax between the groups after treatment. 
PVR was significantly worse in the combination group 
than in the monotherapy group. Thus, clinical usefulness of 
combination therapy was not found in the study. Yokoyama 
et al performed a randomized study to compare the efficacy 
and safety of naftopidil monotherapy (n = 19), propiverine 
monotherapy (n = 18) and combination therapy (n = 21) for 
patients having LUTS/BPH associated with OAB (mean age 
69.1 years). The IPSS did not improve with the propiverine 
monotherapy. On a frequency volume chart, although daytime 
frequency with the naftopidil monotherapy and nighttime 
frequency with the propiverine monotherapy did not improve, 
both significantly improved with the combination therapy. On 
the other hand, PVR significantly increased with the propiv-
erine monotherapy and the combination therapy.
Thus, information on the efficacy and safety of combi-
nation therapy using naftopidil and anticholinergic agents 
is too limited to draw a definitive conclusion. In addition, 
no studies investigated add-on effects of anticholinergic 
agents for patients having remaining OAB after naftopidil 
monotherapy.
Long-term efficacy of naftopidil
Several studies reported on the long-term efficacy of 
α1-blockers over 3 years. Narayan et al demonstrated that 
improvement of LUTS and the flow rate lasted up to 6 years 
when using 0.4 mg or 0.8 mg of tamsulosin in an open-label 
extension study.48 Schulman et al also reported long-term effi-
cacy of up to 4 years with 0.4 mg of tamsulosin in Europe.49 
The MTOPS study and the CombAT study also demonstrated 
the long-term efficacy of doxazosin monotherapy and tam-
sulosin monotherapy, respectively.3–5 However, the long-term 
efficacy of naftopidil over 1 year has not been investigated 
well. In addition, information on the rate of treatment failure 
during long-term follow-up after administration of naftopidil 
is extremely limited.
Masumori et al examined treatment failure during a 
4-year follow-up period after administration of 50 mg/day 
naftopidil for 247 patients (mean age 67.6 years) having 
LUTS/BPH with IPSS $ 8.50 Of the 247, treatment failure 
defined as conversion to other medical treatment or surgery 
occurred in 42 patients (17.0%) during the 4-year follow 
up period. The 4-year treatment failure rate on the Kaplan–
Meier curve was 35.0%. Among the parameters at baseline, 
PV was the only significant determinant of treatment failure. 
Patients with a PV of 35 mL or larger had a 2.1-fold hazard 
of treatment failure compared to those with a PV of smaller 
than 35 mL (95%CI; 1.06–4.33, P = 0.03). Those patients 
having severe IPSS at 12 weeks after administration of 
naftopidil had a 3.5-fold higher hazard than those having 
mild/moderate IPSS (95%CI; 1.34–9.26, P = 0.01). By 4 
years, 200 patients (81%) had quit taking naftopidil because 
of adverse events, treatment failure, loss to follow-up, etc. 
Thus, only 19% were known to continue the same medica-
tion for 4 years in real-life clinical practice. Although similar 
results were reported by de la Rosette et al, indicating that 
the discontinuation rates were 64% after 3 years and 79% 
after 5 years of follow-up after administration of α1-blockers 
such as terazosin, alfuzosin, and tamsulosin, the discontinu-
ation rate was significantly different according to the type 
of α1-blocker.51 Kawachi et al retrospectively compared the 
5-year failure rates of 25–75 mg/day naftopidil (n = 78) and 
0.2 mg of tamsulosin (n = 53) for 131 patients (mean age 66.4 
years) having LUTS/BPH with IPSS $ 8 and a QOL index 
$ 3.52 No significant difference in failure rates was observed 
since 28 patients (35.9%) using naftopidil and 22 (41.4%) 
using tamsulosin discontinued treatment during the follow 
up period. In addition, there were no differences in reasons 
for discontinuation between the groups. Thus the differences 
in the long-term outcomes and discontinuation rates should 
be investigated prospectively.
Kojima et al investigated changes of expression levels of 
α1-AR subtypes in 15 prostates having LUTS/BPH before 
and after administration of 50 mg/day naftopidil for 12 
weeks.53 Naftopidil down-regulated the expression of α1a- 
and α1b-AR subtypes whereas it up-regulated the expression 
of the α1d-AR subtype without a change in the total α1-AR 
mRNA expression level. Although there was no correlation 
between the changes of α1-AR subtype expression levels 
and the short-term efficacy of naftopidil, its long-term use 
may induce therapeutic tolerance because up-regulation of 
the α1d-AR subtype is considered a compensatory adapta-
tion to administration of the chronic α1D-AR antagonist 
naftopidil.
Sexual dysfunction and 
intraoperative floppy iris syndrome
One of the adverse events induced by α1-blockers is ejacu-
latory disorders. The induction of ejaculatory disorders by 
α1-blockers may be determined by the selectivity for the 
α1A-AR subtype. Hisasue et al demonstrated that α1A 
is the dominant subtype in human seminal vesicles (α1a, 
75.0%; α1d, 13.3%; α1b, 11.7%).54 In addition, the study 
of 17 healthy Japanese volunteers showed that 0.2 or 0.4 mg Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of tamsulosin for 3 days resulted in a reduced amount of 
semen, whereas 50 or 100 mg of naftopidil for 3 days did not. 
Since no sperm were detected in the postejaculate midstream 
urine, the ejaculatory dysfunction induced by tamsulosin is 
thought to be due to inhibition of seminal emission rather 
than retrograde ejaculation. Thus, a drug that has higher 
selectivity for the α1A-AR subtype seems to easily cause 
ejaculatory dysfunction, mainly through the inhibition of 
seminal emission.
Masumori et al performed a randomized prospective study 
to investigate the incidence of ejaculatory disorders caused 
by 50 mg of naftopidil (n = 48) and 0.2 mg of tamsulosin 
(n = 47). Among men who had sexual activity during the 12 
weeks, the proportion who reported an abnormal feeling on 
ejaculation was higher in the tamsulosin group (16.7%) than 
in the naftopidil group (7.4%), although the difference was not 
significant (P = 0.402). The proportion of men who reported 
reduced ejaculatory volume after treatment was significantly 
higher in the tamsulosin group (96.0%) than in the naftopidil 
group (73.1%, P = 0.0496). Although the improvement of 
erectile function by α1-blockers has been reported,55,56 no sig-
nificant change in the International Index of Erectile Function 
(IIEF)-5 score caused by either drug was observed in this small 
study. On the other hand, Yokoyama et al showed that the mean 
IIEF-5 score improved in a nafopidil group (7.0 at baseline to 
7.6 at 3 months, P = 0.013) but not in a silodosin group (6.2 
at baseline to 5.0 at 3 months, P = 0.682) or tamsulosin group 
(6.6 at baseline to 5.2 at 3 months, P = 0.342).32 The propor-
tion of newly developed reduced volume of ejaculation was 
relatively high in the silodosin group (10/41, 24.4%). However, 
there was no significant difference between naftopidil (1/42, 
2.4%) and tamsulosin (1/39, 2.6%). Thus, naftopidil may be 
applicable for relatively young patients who are sexually active 
and want to avoid ejaculatory disorders.
Intraoperative floppy iris syndrome (IFIS) has been 
reported as one of the adverse events of α1-blockers. The 
FDA issued a labeling change for tamsulosin warning 
of the possibility of IFIS in 2005. There is a prospective 
multicenter study that investigated the incidence of IFIS.57 
In 2,643 consecutive eyes of 1,968 patients (1,015 eyes of 
762 male patients and 1,628 eyes of 1,206 female patients) 
who received cataract surgery, IFIS was observed in 29 eyes 
(1.1%) of 25 male patients, all of whom were receiving sys-
temic α1 blockers. Of the 58 eyes of 50 patients who took 
tamsulosin, 25 eyes (43.1%) developed IFIS. Of the 21 eyes 
of 19 patients receiving naftopidil, IFIS was observed in 4 
eyes (19.0%). Thus, the incidence of IFIS was significantly 
higher with tamsulosin than with naftopidil (P = 0.042). 
On the other hand, no IFIS was observed in patients using 
nonselective α1-blockers such as prazosin and terazosin. 
Thus, α1-blockers having higher affinity for the α1A-AR 
subtype are likely to cause IFIS as well as ejaculatory 
disorders.
QOL and naftopidil
Two studies mainly investigated QOL using a question-
naire. Komiya et al demonstrated that LUTS/BPH impaired 
generic QOL evaluated by the Short Form-8 (SF-8), that 
was improved by naftopidil treatment.58 Awa et al showed 
that naftopidil significantly improved 7 domains, though not 
general health perceptions and social limitations, in the King’s 
Health Questionnaire (KHQ) having 9 domains consisting 
of 21 questions.59
Conclusions
Naftopidil is clinically available only in Japan. There are 
no data derived from white or black men living in western 
countries. Thus, it remains unknown if the efficacy and 
safety of naftopidil in the Japanese and Asian population are 
applicable to others. In addition, well-designed prospective 
large-scale clinical studies having adequate statistical power 
to draw solid conclusions are lacking. On the other hand, 
the possible low incidence of sexual dysfunction caused by 
naftopidil is attractive. Further comparative short-term and 
long-term studies including evaluation of sexual function are 
mandatory. In addition, studies in real life clinical practice 
are necessary to apply the results obtained by randomized 
controlled studies to the general population.
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